TY - JOUR
T1 - Development of selective medium for IMP-type carbapenemase-producing Enterobacteriaceae in stool specimens
AU - Yamamoto, Norihisa
AU - Kawahara, Ryuji
AU - Akeda, Yukihiro
AU - Shanmugakani, Rathina Kumar
AU - Yoshida, Hisao
AU - Hagiya, Hideharu
AU - Hara, Naohiro
AU - Nishi, Isao
AU - Yukawa, Satomi
AU - Asada, Rumiko
AU - Sasaki, Yumi
AU - Maeda, Kazuhiro
AU - Sakamoto, Noriko
AU - Hamada, Shigeyuki
AU - Tomono, Kazunori
N1 - Funding Information:
This study was supported by the Community-based Health Promotion Project from Osaka Prefecture, the Infection Control Budget from Osaka University Hospital, Japan Initiative for Global Research Network on Infectious Diseases (J-GRID) from Ministry of Education, Culture, Sport, Science and Technology in Japan (MEXT), and Japan Agency for Medical Research and Development (AMED).
Publisher Copyright:
© 2017 The Author(s).
PY - 2017/3/24
Y1 - 2017/3/24
N2 - Background: Identification of carbapenemase-producing Enterobacteriaceae (CPE) in faecal specimens is challenging. This fact is particularly critical because low-level carbapenem-resistant organisms such as IMP-producing CPE are most prevalent in Japan. We developed a modified selective medium more suitable for IMP-type CPE. Methods: Fifteen reference CPE strains producing different types of β-lactamases were used to evaluate the commercially available CHROMagar KPC and chromID CARBA as well as the newly prepared MC-ECC medium (CHROMagar ECC supplemented with meropenem, cloxacillin, and ZnSO4) and M-ECC medium (CHROMagar ECC supplemented with meropenem and ZnSO4). A total of 1035 clinical samples were then examined to detect CPE using chromID CARBA and M-ECC medium. Results: All tested strains producing NDM-, KPC-, and OXA-48-carbapenemases were successfully cultured in the media employed. Although most of the IMP-positive strains did not grow in CHROMagar KPC, chromID CARBA, or MC-ECC, all tested strains grew on M-ECC. When faecal samples were applied to the media, M-ECC medium allowed the best growth of IMP-type CPE with a significantly higher sensitivity (99.3%) than that of chromID CARBA (13.9%). Conclusions: M-ECC medium was determined as the most favourable selective medium for the detection of IMP-type CPE as well as other types of CPE.
AB - Background: Identification of carbapenemase-producing Enterobacteriaceae (CPE) in faecal specimens is challenging. This fact is particularly critical because low-level carbapenem-resistant organisms such as IMP-producing CPE are most prevalent in Japan. We developed a modified selective medium more suitable for IMP-type CPE. Methods: Fifteen reference CPE strains producing different types of β-lactamases were used to evaluate the commercially available CHROMagar KPC and chromID CARBA as well as the newly prepared MC-ECC medium (CHROMagar ECC supplemented with meropenem, cloxacillin, and ZnSO4) and M-ECC medium (CHROMagar ECC supplemented with meropenem and ZnSO4). A total of 1035 clinical samples were then examined to detect CPE using chromID CARBA and M-ECC medium. Results: All tested strains producing NDM-, KPC-, and OXA-48-carbapenemases were successfully cultured in the media employed. Although most of the IMP-positive strains did not grow in CHROMagar KPC, chromID CARBA, or MC-ECC, all tested strains grew on M-ECC. When faecal samples were applied to the media, M-ECC medium allowed the best growth of IMP-type CPE with a significantly higher sensitivity (99.3%) than that of chromID CARBA (13.9%). Conclusions: M-ECC medium was determined as the most favourable selective medium for the detection of IMP-type CPE as well as other types of CPE.
KW - Carbapenemase-producing Enterobacteriaceae
KW - Faecal specimens
KW - IMP
KW - Selective culture medium
UR - http://www.scopus.com/inward/record.url?scp=85016139048&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85016139048&partnerID=8YFLogxK
U2 - 10.1186/s12879-017-2312-1
DO - 10.1186/s12879-017-2312-1
M3 - Article
C2 - 28340557
AN - SCOPUS:85016139048
SN - 1471-2334
VL - 17
JO - BMC Infectious Diseases
JF - BMC Infectious Diseases
IS - 1
M1 - 229
ER -
